123 related articles for article (PubMed ID: 19199267)
1. An improved prognostic parameter for non-Hodgkin's lymphoma based on the combination of three serum tumor markers.
Gui W; Wang T; Wang J; Wang L; He J; Yang B; Zhao Z; Zhang H; Zhang Q
Int J Biol Markers; 2008; 23(4):207-13. PubMed ID: 19199267
[TBL] [Abstract][Full Text] [Related]
2. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
4. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma.
Wu L; Wang T; Gui W; Lin H; Xie K; Wang H; Gao T; Zhang X; Liu L; Han T; Tian Y; Hou L
Oncology; 2014; 87(1):40-7. PubMed ID: 24969158
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
8. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
Duan Y; Li G; Hu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
[TBL] [Abstract][Full Text] [Related]
11. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy.
Morra E
Int J Biol Markers; 1999; 14(3):149-53. PubMed ID: 10569136
[TBL] [Abstract][Full Text] [Related]
12. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
Chen W; Luo RC; Fan WW; Ma SD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
[TBL] [Abstract][Full Text] [Related]
18. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
[TBL] [Abstract][Full Text] [Related]
19. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
20. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]